Breaking News

MethylGene Makes Management Changes

March 15, 2013

Besterman, Baum and Gergen assume new roles

Jeffrey M. Besterman, Ph.D., has been appointed executive vice president of R&D and chief scientific officer at MethylGene, Inc. Joe Walewicz, vice president of business and corporate development, and Klaus B. Kepper, vice president finance and chief financial officer, will be leaving the company.
Dr. Charles Baum, chief executive officer, will take over Dr. Besterman’s responsibilities and Mark Gergen, chief operating officer has assumed the responsibilities of Mr. Kepper and Mr. Walewicz. 
"I want to personally thank Klaus, Jeff and Joe for their contributions to MethylGene," said Dr. Baum. “We wish them the best in their future pursuits.”